Chinese health expert: local production of Paxlovid should be able to start soon

BEIJING (Reuters) - Supplies of Pfizer's Paxlovid in China are still unable to meet demand but local production of the anti-viral COVID drug should be able to start soon, a Chinese health expert said on Wednesday.

Wang Qingquan, head of the infectious diseases department at Peking University First Hospital, made the comment at a press conference.

(Reporting by Yew Lun Tian; Writing by Brenda Goh; Editing by Jacqueline Wong)